3 hours ago
Data from 2 studies presented at ACR 2024 demonstrate the potential of AI to improve access to quality rheumatological assessments.
4 hours ago
Stephen Nicholls, MBBS, PhD, provides additional insight into KRAKEN trial data and the potential of muvalaplin.
5 hours ago
Marianna Fontana, MD, PhD discusses Phase 1 interim results on the CRISPR-based gene-editing therapy, nex-z, for ATTR-CM.
6 hours ago
This analysis evaluated the frequency of peanut-sensitized infants and toddlers being sensitized to other types of nuts.
8 hours ago
Stephen J. Nicholls, MD, PhD discusses the robust efficacy and tolerability of zerlasiran for Lp(a) lowering, paving the way for Phase 3 development.